JP Morgan Chase
RCUS icon

JP Morgan Chase’s Arcus Biosciences RCUS Stock Holding History

JP Morgan Chase’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$932K Buy
+30,000
New +$741K ﹤0.01% 4718
2024
Q1 		– Sell
-500
Closed -$9.55K – 7802
2023
Q4 		$9.55K Sell
500
-1,700
-77% -$27.2K ﹤0.01% 6413
2023
Q3 		$39.5K Sell
2,200
-49,400
-96% -$993K ﹤0.01% 5869
2023
Q2 		$1.05M Buy
+51,600
New +$983K ﹤0.01% 4027
2021
Q3 		– Sell
-65,000
Closed -$1.78M – 6728
2021
Q2 		$1.78M Buy
+65,000
New +$1.86M ﹤0.01% 3876

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

JP Morgan Chase's RCUS Position: Q2 2026 in Review

JP Morgan Chase increased its Arcus Biosciences (RCUS) stake by 418% in Q2 2026, buying an estimated $8.34M and bringing the position to 418,243 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2573.

JP Morgan Chase first reported a position in RCUS in Q1 2018 and has held it in 34 quarters since. The position peaked at $13.8M in Q1 2022. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • JP Morgan Chase held 418,243 shares of Arcus Biosciences worth $13.1M as of Q2 2026.
  • JP Morgan Chase bought 337,426 Arcus Biosciences shares in Q2 2026, an estimated $8.34M.
  • Arcus Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2573 holding.
  • JP Morgan Chase first reported a position in Arcus Biosciences in Q1 2018 and has held it in 34 quarters since.
  • JP Morgan Chase's Arcus Biosciences position peaked at $13.8M in Q1 2022.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.